For Further Information Contact:

Tony Deasey                                    IraWeingarten/SteveChizzik
Celsion Corporation                            EquityCommunications
410.290.5390                                   888.530.7051
tony@celsion.com                               equity@silcom.com

FOR IMMEDIATE RELEASE

   CELSION FILES IND TO INITIATE UNIQUE THERAPY FOR TREATMENT OF PROSTATE CANCER

COLUMBIA, MARYLAND - APRIL 8, 2002: CELSION CORPORATION (AMEX: CLN) today
announced plans to undertake human clinical trials for a unique cancer therapy
that, according to its chief investigator, has been successfully applied in
small animal studies "with profound biological effect on the prostate, and with
no apparent safety concerns." On March 29, 2002, Celsion filed an
Investigational New Drug application (IND) with the Food and Drug Administration
for the use of its patented, heat-activated liposome compound in the treatment
of prostate cancer. Liposomes are man-made microscopic spheres with a lipid
membrane, which can encapsulate drugs, used for targeted "drug" delivery in the
body. The experimental treatment system employs Celsion's Microfocus BPH 800
Microwave Urethroplasty (TM) system as the means of heat activation.

According to Dr. David Needham, Professor of Material Sciences, Department of
Mechanical Engineering and Material Science at Duke University and the inventor
of this temperature-sensitive liposome, the technology employs a specially
designed liposome, which opens when heated. When a compound consisting of the
anticancer drug encapsulated in these liposomes is injected into the bloodstream
of a cancer patient and the cancer treatment site is subjected to mild heat, the
liposomes open and rapidly release their contents of chemotherapeutic drugs
directly at the treatment site. This release process is significantly more rapid
than in conventional liposomal therapy. As reported in Cancer Research -
Advances in Brief (March 1, 2000), this increased concentration of drug in the
treatment area caused long-term complete regression of tumors in all of the mice
treated in the initial small animal studies. Celsion holds exclusive license
from Duke University for the use of Duke's patented temperature-sensitive
liposome technology.

Upon clearance of the IND by the FDA, the Company plans to undertake Phase I
clinical trials at Roswell Park Cancer Institute in Buffalo, New York, one of
the leading cancer centers in the U.S. A formulation combining Celsion's
site-specific, temperature-sensitive liposomes and Adriamycin (generically known
as doxorubicin), which is manufactured by Pharmacia (NYSE:PHA), will be used to
treat patients suffering from prostate cancer.

According to Dr. Bill Gannon, Celsion's Medical Director, "the intent of our
Phase I clinical trial will be to determine the maximum safely tolerated dose of
Adriamycin, delivered by our temperature-sensitive liposomes, in patients
receiving therapy." Dr. Donald Trump, Senior Vice President for Clinical
Research, at the Roswell Park Cancer Institute, and a national cancer leader in
innovative clinical trials and chemo-prevention studies in prostate cancer,
stated, "My colleagues and I are excited about the opportunity to work on the
development of this new and potentially important approach to the treatment of
prostate cancer. The use of heat-activated liposomes may allow the direct
delivery of high-dose chemotherapy to the tumor, thus minimizing the need for
invasive surgery, as well as the severe toxicities associated with currently
available anticancer drugs. Our pre-clinical studies at Roswell Park have shown
that, with regard to the animals in the studies, the release of drugs from
heat-sensitive liposomes results in profound biological effects on the prostate
gland with no apparent safety concerns such as urinary tract blockage." Dr.
Trump will be supported by Dr. Peter Kanter, a recognized expert in the
toxicological effects of liposomal compounds, who conducted the toxicity studies
in animals for this compound.

"We anticipate that this will be the first of several studies using our
temperature-sensitive, drug-laden liposomes in conjunction with our proprietary
focused-heating microwave systems to treat cancer. We plan additional trials
targeting not only prostate, but also liver, ovarian, breast and other cancers,"
according to Gannon. Celsion plans to use Adaptive Phased Array heating
technology, for which Celsion holds an exclusive license from the Massachusetts
Institute of Technology to provide heating for future developments.
Additionally, Celsion has contracted with The National Institutes of Health to
supply temperature-sensitive liposomes for pre-clinical studies for potential
use in the treatment of liver cancer.

Dr. Augustine Cheung, Celsion's Chief Executive Officer and Founder stated, "The
filing of this IND marks another important milestone for Celsion. Demonstrating
that the combination of our focused-heat therapy and temperature-sensitive
liposomes can be effective in the treatment of prostate cancer is a first step.
This combination could serve as a platform for our expansion into other types of
cancer treatment, including the use of our temperature-sensitive liposome
technology to encapsulate other drugs. This program, in conjunction with our
ongoing pivotal breast cancer trials, in which we are attempting to demonstrate
that heat alone can ablate small breast cancer tumors and, in combination with
chemotherapy, shrink large breast cancer tumors, should provide a strong basis
for Celsion's position in the cancer therapeutic market."

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a research
and development company dedicated to commercializing medical treatment systems
for cancer and other diseases using focused heat technology delivered by
patented microwave technology. Celsion has research, license or
commercialization agreements with leading institutions such as Duke University
Medical Center, Massachusetts Institute of Technology, Roswell Park Cancer
Institute, Harbor UCLA Medical Center, the Center for Breast Surgery at Columbia
Hospital in Florida, Montefiore Medical Center and Memorial Sloan Kettering
Cancer Center in New York. For more information on Celsion, visit our website:
http//www.celsion.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; possible changes in
cost and timing of development and testing, capital structure, and other
financial items; changes in approaches to medical treatment; introduction of new
products by others; possible acquisitions of other technologies, assets or
businesses; possible actions by customers, suppliers, competitors, regulatory
authorities; and other risks detailed from time to time in the Company's
periodic reports filed with the Securities and Exchange Commission.

                                      ####